Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC raised its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,531,498 shares of the specialty pharmaceutical company’s stock after buying an additional 113,300 shares during the quarter. Renaissance Technologies LLC’s holdings in Collegium Pharmaceutical were worth $49,314,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its position in shares of Collegium Pharmaceutical by 2.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company’s stock valued at $33,457,000 after acquiring an additional 19,876 shares in the last quarter. BOKF NA acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth about $490,000. American Century Companies Inc. grew its holdings in shares of Collegium Pharmaceutical by 8.8% during the second quarter. American Century Companies Inc. now owns 99,808 shares of the specialty pharmaceutical company’s stock worth $3,214,000 after buying an additional 8,097 shares in the last quarter. Choreo LLC acquired a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $396,000. Finally, Quest Partners LLC raised its position in shares of Collegium Pharmaceutical by 186.0% in the second quarter. Quest Partners LLC now owns 18,827 shares of the specialty pharmaceutical company’s stock valued at $606,000 after buying an additional 12,244 shares during the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $37.38 on Wednesday. Collegium Pharmaceutical, Inc. has a 12 month low of $20.95 and a 12 month high of $40.95. The business has a 50-day moving average of $35.65 and a two-hundred day moving average of $35.41. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The firm has a market capitalization of $1.20 billion, a PE ratio of 15.58 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. During the same quarter in the prior year, the business earned $1.13 earnings per share. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

COLL has been the subject of several recent analyst reports. Truist Financial lifted their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and issued a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.